Hims & Hers Health (NYSE:HIMS) Insider Sells $100,957.37 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,461 shares of the business’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $29.17, for a total value of $100,957.37. Following the completion of the sale, the insider owned 300,809 shares of the company’s stock, valued at $8,774,598.53. The trade was a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.86, for a total value of $173,734.96.
• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.33, for a total transaction of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Trading Down 0.1%

Shares of HIMS opened at $28.96 on Monday. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30. The firm has a market cap of $6.76 billion, a price-to-earnings ratio of -45.97 and a beta of 2.44. The firm has a 50 day moving average price of $29.28 and a 200-day moving average price of $28.27. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.17 EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently made changes to their positions in the business. Cunning Capital Partners LP bought a new stake in Hims & Hers Health in the fourth quarter valued at $1,110,000. B. Metzler seel. Sohn & Co. AG purchased a new position in Hims & Hers Health during the 2nd quarter valued at $2,992,000. Virtu Financial LLC purchased a new position in Hims & Hers Health during the 4th quarter valued at $1,937,000. Norges Bank bought a new position in Hims & Hers Health in the 4th quarter worth $62,153,000. Finally, Louisiana State Employees Retirement System bought a new position in Hims & Hers Health in the 1st quarter worth $1,254,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers and Hims Australia announced new management appointments, including chief medical officers for the UK and Australia. The moves could strengthen local clinical oversight and support the company’s international expansion strategy. Hims & Hers Names Chief Medical Officers in the UK and Australia
• Neutral Sentiment: Two insiders sold a combined 5,461 shares for approximately $160,357. Soleil Boughton sold 3,461 shares at an average of $29.17, while CFO Oluyemi Okupe sold 2,000 shares at $29.70. Both transactions were executed under pre-arranged Rule 10b5-1 plans, and each insider retained substantial holdings, reducing the significance of the sales as a standalone signal. SEC insider filing
• Negative Sentiment: Several law firms publicized a securities-fraud class action against Hims & Hers and certain executives. The lawsuit follows the FTC’s federal complaint, which allegedly concerns deceptive business practices and privacy-related misstatements or omissions. Investors who purchased shares between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates legal costs, reputational risk, and uncertainty around potential financial liability. Hagens Berman class-action announcement

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Barclays lowered their target price on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a research note on Friday, August 21st. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. JPMorgan Chase & Co. initiated coverage on shares of Hims & Hers Health in a report on Friday, September 11th. They issued a “neutral” rating and a $32.00 target price on the stock. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Finally, Bank of America increased their price target on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.